Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin plus basal insulin versus basal-bolus insulin in hospitalized adults with uncontrolled type 2 diabetes
MOH_2017-10-08_000855Phase 4Not yet recruiting
- Sponsor
- דר דרור דיקר
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by דר דרור דיקר. Primary endpoints: Mean daily blood glucose difference between treatment groups and Hypoglycemia events. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2017-10-08_000855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-08_000855.